ADAR1 mediated glioma-associated oncogene 1 (GLI1) editing leads to an R/G amino acid change at residue 701, which is significantly higher in relapsed multiple myeloma (MM) than age matched controls [42] (Table 1). This evidence concerns the gene GLI1 and Miyoshi myopathy.